Access
Compounding pharmacies for tirzepatide: what to verify now
Older pharmacy rankings relied on shortage-era assumptions. Current tirzepatide compounding decisions need a patient-specific medical rationale and compliance with the applicable conditions.
Why shortage-era advice is outdated
FDA determined the tirzepatide shortage resolved in December 2024 and the semaglutide injection shortage resolved in February 2025. The agency's current clarification describes restrictions on regular or inordinate compounding of essentially copies under section 503A and separate conditions for 503B outsourcing facilities.
A website continuing to offer a product does not prove that the prescription and production meet those conditions. Nor does shortage resolution mean that every possible patient-specific compounded prescription is categorically prohibited. A clinician and pharmacist must assess the actual circumstances.
Sources: FDA clarification of compounding policies as GLP-1 supply stabilizes
Verify the actual dispensing entity
A telehealth platform may arrange care without manufacturing or dispensing medicine. Ask for the pharmacy's legal name, state license, physical location, and the product label. Review the license with the relevant state board, rather than relying on a platform logo or claim about a registered facility.
Registration or an outsourcing-facility listing is not FDA approval of the medicine. A laboratory certificate can describe a test, but it does not establish sterility, clinical outcomes, legal eligibility, or the identity of every vial you might receive.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Assess the formulation and instructions
Ask the pharmacist to identify every ingredient and the reason for additives such as B6 or B12. Their presence does not demonstrate that a preparation is clinically equivalent to Zepbound or Mounjaro or automatically satisfies a compounding exception.
Obtain dose, concentration, volume, syringe, storage, and beyond-use instructions. A vial concentration change can alter the volume required even if prescribed milligrams stay the same. Do not copy a branded pen's directions.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Questions for a clinician-led decision
Discuss whether an FDA-approved product can meet the medical need, what specific difference is necessary if it cannot, and what alternatives exist. Cost and coverage should be discussed honestly without converting affordability concerns into an unproven safety claim.
Ask how adverse events are handled and who provides follow-up. Evidence from branded-drug trials does not establish the compounded formulation's results. If the pharmacy or clinical rationale remains unclear, request documentation before treatment.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Distinguish an approved vial from a compounded formula
Zepbound and Mounjaro labeling includes approved presentations beyond a familiar pen. A vial is a delivery format, not a regulatory category. Ask whether the dispensed vial is the named approved product or a preparation made by a compounding pharmacy. The answer determines which label, instructions, evidence, and pricing pathway should be used.
A compounded tirzepatide formula with B6, B12, or another addition remains separate from the approved branded product. A vitamin does not establish improved weight reduction, fewer gastrointestinal effects, or equivalence to the branded trial. Ask what evidence supports the actual combination and why an approved product cannot meet the patient's medical need. A pharmacy's identity and license should be verified independently of those clinical and formulation questions.
Sources: Zepbound prescribing information · Mounjaro prescribing information · FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA BeSafeRx: checking an online pharmacy
Why an old pharmacy recommendation may no longer apply
FDA determined the tirzepatide shortage resolved in December 2024. Its current clarification describes the resulting restrictions and different conditions for 503A pharmacies and 503B outsourcing facilities. An article written during the shortage may therefore recommend access arrangements that cannot simply be carried forward as routine practice.
Ask the clinician and pharmacy to explain the current patient-specific rationale and applicable conditions rather than citing an old shortage announcement. A statement that compounding exists legally does not prove every offered preparation meets those conditions, while shortage resolution does not mean every patient-specific compound is categorically unlawful. Keep both boundaries visible. This review does not offer a legal certification of any pharmacy; it gives a framework for requesting a current explanation of the actual prescription.
Sources: FDA clarification of compounding policies as GLP-1 supply stabilizes · FDA concerns with unapproved GLP-1 drugs used for weight loss
Evaluate the refill instructions and clinical continuity
Request the ingredient list, concentration, intended milligrams, volume, syringe specification, storage, and beyond-use directions. If any change occurs, old unit markings must be checked again. A chart for a branded pen does not supply the correct syringe measurement for a different vial. Ask for a demonstration and a pharmacist contact route.
Also establish who assesses symptoms and dose changes. Tirzepatide-related clinical precautions, including contraception and interactions, should be discussed with the prescriber; a lower price or a custom formula does not make the assessment unnecessary. Ask what happens if treatment is interrupted or a quality concern arises. Those details are more decision-useful than an unverified claim of best purity, fastest support, or guaranteed trial-average weight loss. We have not independently audited those outcomes for the listed services.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · Zepbound prescribing information · Mounjaro prescribing information
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.